Wed, April 6, 2022
Tue, April 5, 2022
Mon, April 4, 2022
Sun, April 3, 2022
Fri, April 1, 2022
Thu, March 31, 2022
Wed, March 30, 2022
Tue, March 29, 2022
Mon, March 28, 2022

Silvan Tuerkcan Maintained (TSHA) at Buy with Decreased Target to $36 on, Apr 1st, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. with-decreased-target-to-36-on-apr-1st-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Silvan Tuerkcan of JMP Securities, Maintained "Taysha Gene Therapies, Inc." (TSHA) at Buy with Decreased Target from $44 to $36 on, Apr 1st, 2022.

Silvan has made no other calls on TSHA in the last 4 months.



There are 3 other peers that have a rating on TSHA. Out of the 3 peers that are also analyzing TSHA, 0 agree with Silvan's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Silvan


  • Jack Allen of "Baird" Initiated at Buy and Held Target at $26 on, Wednesday, March 9th, 2022
  • Yanan Zhu of "Wells Fargo" Initiated at Buy and Held Target at $25 on, Tuesday, March 1st, 2022
  • Debjit Chattopadhyay of "Guggenheim" Initiated at Strong Buy and Held Target at $28 on, Thursday, December 16th, 2021

Publication Contributing Sources